Vivos Therapeutics (NASDAQ: VVOS) reported Q2 EPS of ($0.31), $0.06 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.15 million versus the consensus estimate of $5.57 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.